Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 400 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

Združene države Amerike - angleščina - NLM (National Library of Medicine)

terrain pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recomm

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - lidocaine is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. it is also useful for reducing gagging during the taking of x-ray pictures and dental impressions. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type, or to other components of the solution.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

b. braun medical limited - lidocaine hydrochloride monohydrate - solution for injection - 2 percent weight/volume - amides; lidocaine

Irska - angleščina - HPRA (Health Products Regulatory Authority)

b. braun medical limited - lidocaine hydrochloride monohydrate - solution for injection - 1 percent weight/volume - amides; lidocaine

Irska - angleščina - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - lidocaine hydrochloride monohydrate - solution for injection - amides; lidocaine

Irska - angleščina - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - lidocaine hydrochloride monohydrate - solution for injection - amides; lidocaine

Združene države Amerike - angleščina - NLM (National Library of Medicine)

powder pharmaceuticals inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 0.5 mg - zingo™ is indicated for use on intact skin to provide topical local analgesia prior to venipuncture or peripheral intravenous cannulation, in children 3–18 years of age. zingo™ is indicated for use on intact skin to provide topical local analgesia prior to venipuncture  in adults. zingo™ is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. zingo™ was not formally evaluated for effects on reproduction. significant systemic exposure to lidocaine is not expected under recommended conditions of use of zingo™ as lidocaine levels were below the limit of detection in human studies. lidocaine has been previously tested for reproductive toxicity in animal studies, however. the following ratios are based on the assumption that the applied dose is completely absorbed through the skin. pregnancy category b. lidocaine was not teratogenic in rats given subcutaneous doses up to 60 mg/kg [360 mg/m2  or 1200-fold the single dermal administration (sda) of 0.5 mg lidocaine in

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - lidocaine hydrochloride monohydrate 21.32 mg/ml equivalent to lidocaine hydrochloride 20.0 mg/ml - solution for injection - 2% w/v - active: lidocaine hydrochloride monohydrate 21.32 mg/ml equivalent to lidocaine hydrochloride 20.0 mg/ml excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - indicated for the production of local or regional anaesthesia by the following techniques: local infiltration minor or major nerve blocks epidural block arthroscopy intravenous regional anaesthesia